Enhanced therapeutic efficacy by simultaneously targeting two genetic defects in tumors

Molecular Therapy

Volumn 17, Issue 1, 2009, Pages 57-64

  Zhang, He ^a,b   Wang, Haibo ^a,b   Zhang, Jianjun ^a   Qian, Guanxiang ^a   Niu, Beibei ^a   Fan, Xianqun ^a   Lu, Jian ^a   Hoffman, Andrew R ^b   Hu, Ji Fan ^b   Ge, Shengfang ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

H 101; ONCOLYTIC ADENOVIRUS; PROTEIN BCL 2; PROTEIN P53; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ADENOVIRUS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER GENE THERAPY; CANCER INHIBITION; CANCER SURVIVAL; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; FEMALE; GENE INACTIVATION; GENE MUTATION; GENE OVEREXPRESSION; GENE TARGETING; GENETIC DISORDER; HUMAN; HUMAN CELL; MALIGNANT NEOPLASTIC DISEASE; MONOTHERAPY; MOUSE; NONHUMAN; ONCOLYTIC VIROTHERAPY; REGULATORY MECHANISM; SIGNAL TRANSDUCTION; TUMOR XENOGRAFT; VIRUS RECOMBINANT; VIRUS REPLICATION;

ADENOVIRIDAE; ANIMALS; BLOTTING, WESTERN; CELL LINE, TUMOR; GENETIC VECTORS; HUMANS; IMMUNOHISTOCHEMISTRY; MICE; MICE, NUDE; NEOPLASMS; ONCOLYTIC VIRUSES; PROTO-ONCOGENE PROTEINS C-BCL-2; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, SMALL INTERFERING; TUMOR SUPPRESSOR PROTEIN P53;

ADENOVIRIDAE; ANIMALIA;

EID: 58149269305     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2008.236     Document Type: Article

References (48)

1. Olivier, M, Eeles, R, Hollstein, M, Khan, MA, Harris, CC and Hainaut, P (2002). The IARC TP53 database: New online mutation analysis and recommendations to users. Hum Mutat 19: 607-614.
2. Bouchet, BP, de Fromentel, CC, Puisieux, A and Galmarini, CM (2006). p53 as a target for anti-cancer drug development. Crit Rev Oncol Hematol 58: 190-207.
3. Gabrilovich, DI (2006). INGN 201 (Advexin): Adenoviral p53 gene therapy for cancer. Expert Opin Biol Ther 6: 823-832.
4. Merritt, JA, Roth, JA and Logothetis, CJ (2001). Clinical evaluation of adenoviral-mediated p53 gene transfer: Review of INGN 201 studies. Semin Oncol 28: 105-114.
5. Bischoff, JR, Kirn, DH, Williams, A, Heise, C, Horn, S, Muna, M et al. (1996). An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science 274: 373-376.
6. Ries, S and Korn, WM (2002). ONYX-015: Mechanisms of action and clinical potential of a replication-selective adenovirus. Br J Cancer 86 5-11.
7. Wiman, KG (2006). Strategies for therapeutic targeting of the p53 pathway in cancer. Cell Death Differ 13: 921-926.
8. Post, LE (2002). Selectively replicating adenoviruses for cancer therapy: An update on clinical development. Curr Opin Investig Drugs 3: 1768-1772.
9. Yu, W and Fang, H (2007). Clinical trials with oncolytic adenovirus in China. Curr Cancer Drug Targets 7: 141-148.
10. Kasuya, H, Takeda, S, Shimoyama, S, Shikano, T, Nomura, N, Kanazumi, N et al. (2007). Oncolytic virus therapy-foreword. Curr Cancer Drug Targets 7: 123-125.
11. Rothmann, T, Hengstermann, A, Whitaker, NJ, Scheffner, M and zur Hausen, H (1998). Replication of ONYX-015, a potential anticancer adenovirus, is independent of p53 status in tumor cells. J Virol 72: 9470-9478.
12. Goodrum, FD and Ornelles, DA (1998). p53 status does not determine outcome of E1B 55-kilodalton mutant adenovirus lytic infection. J Virol 72: 9479-9490.
13. Mihara, M, Erster, S, Zaika, A, Petrenko, O, Chittenden, T, Pancoska, P et al. (2003). p53 has a direct apoptogenic role at the mitochondria. Mol Cell 11: 577-590.
14. Marchenko, ND, Zaika, A and Moll, UM (2000). Death signal-induced localization of p53 protein to mitochondria. A potential role in apoptotic signaling. J Biol Chem 275: 16202-16212.
15. Fuhrken, PG, Apostolidis, PA, Lindsey, S, Miller, WM and Papoutsakis, ET (2008). Tumor suppressor protein p53 regulates megakaryocytic polyploidization and apoptosis. J Biol Chem 283: 15589-15600.
16. Deng, X, Gao, F, Flagg, T, Anderson, J and May, WS (2006). Bcl2's flexible loop domain regulates p53 binding and survival. Mol Cell Biol 26: 4421-4434.
17. Hockenbery, D, Nunez, G, Milliman, C, Schreiber, RD and Korsmeyer, SJ (1990). Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature 348: 334-336.
18. Chao, DT and Korsmeyer, SJ (1998). BCL-2 family: Regulators of cell death. Annu Rev Immunol 16: 395-419.
19. Reed, JC (1999). Mechanisms of apoptosis avoidance in cancer. Curr Opin Oncol 11: 68-75.
20. Futami, T, Miyagishi, M, Seki, M and Taira, K (2002). Induction of apoptosis in HeLa cells with siRNA expression vector targeted against bcl-2. Nucleic Acids Res Suppl: 251-252.
21. Gibson, SA, Pellenz, C, Hutchison, RE, Davey, FR and Shillitoe, EJ (2000). Induction of apoptosis in oral cancer cells by an anti-bcl-2 ribozyme delivered by an adenovirus vector. Clin Cancer Res 6 213-222.
22. Huang, SL, Wu, Y, Yu, H, Zhang, P, Zhang, XQ, Ying, L et al. (2006). Inhibition of Bcl-2 expression by a novel tumor-specific RNA interference system increases chemosensitivity to 5-fluorouracil in Hela cells. Acta Pharmacol Sin 27: 242-248.
23. Hoffman, AR and Hu, JF (2006). Directing DNA Methylation to Inhibit Gene Expression. Cell Mol Neurobiol 26: 425-438.
24. Liang, XH, Mungal, S, Ayscue, A, Meissner, JD, Wodnicki, P, Hockenbery, D et al. (1995). Bcl-2 protooncogene expression in cervical carcinoma cell lines containing inactive p53. J Cell Biochem 57 509-521.
25. Bressac, B, Galvin, KM, Liang, TJ, Isselbacher, KJ, Wands, JR and Ozturk, M (1990). Abnormal structure and expression of p53 gene in human hepatocellular carcinoma. Proc Natl Acad Sci USA 87: 1973-1977.
26. Friedman, SL, Shaulian, E, Littlewood, T, Resnitzky, D and Oren, M (1997). Resistance to p53-mediated growth arrest and apoptosis in Hep 3B hepatoma cells. Oncogene 15: 63-70.
27. Ding, H, Duan, W, Zhu, WG, Ju, R, Srinivasan, K, Otterson, GA et al. (2003). P21 response to DNA damage induced by genistein and etoposide in human lung cancer cells. Biochem Biophys Res Commun 305: 950-956.
28. Martinez, LA, Naguibneva, I, Lehrmann, H, Vervisch, A, Tchenio, T, Lozano, G et al. (2002). Synthetic small inhibiting RNAs: efficient tools to inactivate oncogenic mutations and restore p53 pathways. Proc Natl Acad Sci USA 99: 14849-14854.
29. Reed, JC (2002). Apoptosis-based therapies. Nat Rev Drug Discov 1: 111-121.
30. Banerjee, D (2001). Genasense (Genta Inc). Curr Opin Investig Drugs 2: 574-580.
31. Cotter, FE (1999). Antisense therapy of hematologic malignancies. Semin Hematol 36: 9-14.
32. Lima, RT, Martins, LM, Guimaraes, JE, Sambade, C and Vasconcelos, MH (2004). Specific downregulation of bcl-2 and xIAP by RNAi enhances the effects of chemotherapeutic agents in MCF-7 human breast cancer cells. Cancer Gene Ther 11: 309-316.
33. Xia, H, Mao, Q, Paulson, HL and Davidson, BL (2002). siRNA-mediated gene silencing in vitro and in vivo. Nat Biotechnol 20: 1006-1010.
34. Paddison, PJ, Caudy, AA, Bernstein, E, Hannon, GJ and Conklin, DS (2002). Short hairpin RNAs (shRNAs) induce sequence-specific silencing in mammalian cells. Genes Dev 16: 948-958.
35. Andersson, MG, Haasnoot, PC, Xu, N, Berenjian, S, Berkhout, B and Akusjarvi, G (2005). Suppression of RNA interference by adenovirus virus-associated RNA. J Virol 79: 9556-9565.
36. Pan, Q, Liu, B, Liu, J, Cai, R, Liu, X and Qian, C (2007). Synergistic antitumor activity of XIAP-shRNA and TRAIL expressed by oncolytic adenoviruses in experimental HCC. Acta Oncol: 1-10.
37. Yoon, AR, Kim, JH, Lee, YS, Kim, H, Yoo, JY, Sohn, JH et al. (2006). Markedly enhanced cytolysis by E1B-19kD-deleted oncolytic adenovirus in combination with cisplatin. Hum Gene Ther 17: 379-390.
38. Abou El Hassan, MA, Braam, SR and Kruyt, FA (2006). A real-time RT-PCR assay for the quantitative determination of adenoviral gene expression in tumor cells. J Virol Methods 133: 53-61.
39. Heise, C, Sampson-Johannes, A, Williams, A, McCormick, F, Von Hoff, DD and Kirn, DH (1997). ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents. Nat Med 3: 639-645.
40. Roulston, A, Marcellus, RC and Branton, PE (1999). Viruses and apoptosis. Annu Rev Microbiol 53: 577-628.
41. Chu, RL, Post, DE, Khuri, FR and Van Meir, EG (2004). Use of replicating oncolytic adenoviruses in combination therapy for cancer. Clin Cancer Res 10: 5299-5312.
42. Chen, HL, Li, T, Qiu, XW, Wu, J, Ling, JQ, Sun, ZH et al. (2006). Correction of aberrant imprinting of IGF2 in human tumors by nuclear transfer-induced epigenetic reprogramming. EMBO J 25: 5329-5338.
43. Hu, JF, Vu, TH and Hoffman, AR (1997). Genomic deletion of an imprint maintenance element abolishes imprinting of both insulin-like growth factor II and H19. J Biol Chem 272: 20715-20720.
44. Hu, JF, Vu, TH and Hoffman, AR (1996). Promoter-specific modulation of insulin-like growth factor II genomic imprinting by inhibitors of DNA methylation. J Biol Chem 271: 18253-18262.
45. Yao, XM, Hu, JF, Daniels, M, Li, T, Yang, YW, Li, ZH et al. (2004). Epigenetic regulation of the taxol resistance associated gene (TRAG-3) in human tumors. Cancer Genet Cytogenet 151: 1-13.
46. Yu, H, Zhao, X, Huang, S, Jian, L, Qian, G and Ge, S (2007). Blocking Notch 1 signaling by RNA interference can induce growth inhibition in HeLa cells. Int J Gynecol Cancer 17: 511-516.
47. Jia, RB, Zhang, P, Zhou, YX, Song, X, Liu, HY, Wang, LZ et al. (2007). VEGF-targeted RNA interference suppresses angiogenesis and tumor growth of retinoblastoma. Ophthalmic Res 39: 108-115.
48. Yao, XM, Hu, JF, Daniels, M, Shiran, H, Zhou, XJ, Yien, HF et al. (2003). A methylated oligonucleotide inhibits IGF2 expression and enhances survival in a model of hepatocellular carcinoma. J Clin Invest 111: 265-273.